Feature|Articles|June 14, 2024
- Pharmaceutical Executive: June 2024
- Volume 44
- Issue 6
Pharmaceutical Executive: June 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive June 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 1 year ago
Beyond the Numbers: Extrapolating Today’s Trends Forwardover 1 year ago
Opposite Spectrumsover 1 year ago
2024 Pharm Exec Top 50 Companiesover 1 year ago
Craig Tooman: Silencing the Distractionsover 1 year ago
Regaining Trust in the Pharma Industryover 1 year ago
The Healthcare System is Changing—So How Should We Respond?over 1 year ago
Biotech Performance Remains Tethered to Rate Expectationsover 1 year ago
Pharm Exec Exclusive: Mark Cuban Talks Drug PricingNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
JP Morgan 2026 Preview: Eli Lilly Seeks Bounce Back
2
AstraZeneca Reaches $2 Billion License Agreement with Jacobio Pharma for Pan-KRAS Inhibitor
3
Alnylam Announces $250 Million Investment in Massachusetts Facility
4
President Trump Announces Nine More TrumpRx Participants
5

